Form 4: Amphastar Director Diane Gerst Receives Equity Grant

Director Diane Gerst acquired 8,143 restricted stock units and 17,365 stock options as part of an annual equity compensation grant.

Summary

• Director Diane Gerst was granted 8,143 restricted stock units (RSUs) on June 1, 2026.
• The director also received a stock option grant for 17,365 shares with an exercise price of $18.42.
• Both the RSUs and the stock options are scheduled to vest in full on June 1, 2027.
• Following these transactions, the director's direct beneficial ownership of common stock increased to 31,899 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Equity grants align director interests with long-term shareholder value.
• The vesting schedule encourages retention of board leadership for at least the next year.

Negatives

• The issuance of new equity results in minor dilution for existing shareholders.

Risks

• Future share price volatility could impact the ultimate value of the granted options.
• The exercise price of $18.42 is subject to market fluctuations relative to the company's future performance.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a standard disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that standard annual equity grants for board members are common practice in the pharmaceutical sector to ensure alignment between independent directors and corporate performance goals.

Comparison to Industry Standards

• The grant structure of RSUs and options is consistent with standard corporate governance practices for mid-cap pharmaceutical companies.
• Vesting periods of one year for director equity are standard within the industry.

Stakeholder Impact

• Shareholders experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of equity grants on June 1, 2027.

Key Dates

Keywords

Amphastar Pharmaceuticals, AMPH, Form 4, Insider Trading, Equity Compensation, Director Compensation